Erius syrup from allergies, 60 ml, Bayer

Description

Composition
Active substance:
1 ml contains: Desloratadine (micronized) 0,5 mg.
Excipients:
Propylene glycol 100 mg Sorbitol 150 mg, 0.5 mg citric acid, sodium citrate dihydrate, 1.26 mg, 1 mg of sodium benzoate, disodium edetate 0.25 mg, 490 mg sucrose, flavoring No 15,864 0.75 mg, dye solar sunset yellow 0.023 mg purified water ad 1 ml.
Transparent orange liquid.
Description:
Aerius – syrup from allergies for adults and children, the active substance desloratadine.
You are looking for a cure for allergies in children?
Aerius syrup in the form of the latest generation of the drug, c triple activity against allergy: anti-inflammatory, anti-histamine and anti-allergic (1), which can take children from 6 months.
Aerius 10 helps eliminate allergy symptoms:
– Itching, redness, and tearing eyes;
– congestion, sneezing, itching and runny nose;
– Itching of the sky;
– Itching of the skin, rash.
The drug is indicated:
– with seasonal and perennial allergic rhinitis,
– when krapivnitseSirop Aerius helps to alleviate allergy symptoms in children.
It surpasses some antihistamines II generation (2) on the important properties for children:
– does not cause drowsiness (possible frequency of less than 1 in 10 000 patients);
– does not interact with other drugs;
– can be applied regardless of the meal.
Method of application: 1 times a day, is able to act for 30 minutes and 24 hours to maintain the effect. Dosed depending on the child’s age (6 months 12 years and older)
.
(1). . Canonica GW, Blaiss M. Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011 Feb; 4 (2): 47-53.
(2). For example, drowsiness while taking cetirizine reaches 1.8% in children from 6 months. up to 12 years and up to 9.63% in adults, the simultaneous use of cetirizine drugs depressing the central nervous system, may further reduce the concentration and speed of reactions (Zirtek instructions for use of the drug); levocetirizine should be taken at meal time or on an empty stomach (instructions for use of the drug Suprastineks) ”
Product form:
Syrup 0.5 mg / ml. 30, 50, 60, 100, 120, 150, 225 or 300 ml of syrup in dark glass bottles, sealed with screw caps polypropylene with polyethylene liners having protective device from opening by children. 1 bottle complete with a dosing spoon from a transparent plastic or syringe, graded for measuring the required amount of syrup, together with instructions for use in a cardboard package.
Contraindications
Hypersensitivity to desloratadine, other ingredients or loratadine.
Pregnancy and breast-feeding.
Children up to age 6 months.
Genetically transmitted diseases: fructose intolerance, impaired glucose absorption – galactose deficiency or sucrase – isomaltase in the body (due to the presence of sucrose and sorbitol, in the composition).
CAREFULLY.
Severe renal insufficiency.
Dosage
0.5 mg / ml
Indications
A llergichesky rhinitis (elimination or alleviation of sneezing, nasal congestion, nasal mucus, itching nose, palate pruritus, itching and redness of the eyes, tearing).
Urticaria (reduction or elimination of itching, rashes).
Interaction with other drugs
Interactions with other drugs have been identified in studies with azithromycin, ketoconazole, erythromycin, fluoxetine and cimetidine. Eating does not affect the efficacy of the drug. Erius® does not increase the alcohol effects on the central nervous system. However, during the post-marketing use of cases of intolerance to alcohol and intoxication have been reported. Therefore desloratadine with alcohol should be used with caution.
Overdose
Symptoms. Receiving a dose higher than the recommended 5 times, does not cause any – any symptoms. In clinical trials, daily application for adults and adolescents desloratadine at a dose of 20 mg for 14 days is not associated with a statistically or clinically significant changes of the heart – 5 vascular system. In clinical – pharmacological study of the use of desloratadine in a dose of 45 mg per day (at 9 times the recommended) for 10 days did not cause QT interval elongation and the appearance was not accompanied by serious side effects.
Treatment. In case of accidental ingestion of large amounts of the drug should contact a doctor immediately. Recommended gastric lavage, administration of activated charcoal; if necessary – symptomatic therapy. Desloratadine does not appear in hemodialysis, peritoneal dialysis efficacy has not been established.
pharmachologic effect
Pharmacological group:
Antiallergic agent – H 1 – histamine receptor blocker.
Pharmacodynamics:
Non-sedating long acting antihistamine. It is the primary active metabolite of loratadine. Inhibits histamine release from mast cells. Inhibits the cascade of allergic inflammation, including release of pro-inflammatory cytokines including the interleukins IL – 4, IL – 6, IL – 8, IL – 13, the allocation of adhesion molecules such as P – selectin. Thus, it prevents the development and facilitates the allergic reactions, and possesses protivoekssudativnoe antipruritic effect, reduces capillary permeability, prevents the development of edema, smooth muscle spasm.
The drug has no effect on central nervous system, does not cause drowsiness (the use of desloratadine in the recommended dosage of 5 mg per day are not accompanied by an increase in the incidence of somnolence as compared to the placebo group), and does not affect the speed of psychomotor reactions. In clinical – pharmacological studies of desloratadine at the recommended therapeutic dose were observed lengthening of the QT interval on the electrocardiogram.
Action Erius® preparation starts within 30 minutes after ingestion and continues for 24 hours.
Pharmacokinetics:
Desloratadine is well absorbed in the gastro – intestinal tract. Determined in blood plasma within 30 minutes after ingestion. The maximum concentration is achieved after an average of 3 hours after ingestion. It does not cross the blood-brain barrier. Communication with the plasma protein is 83 – 87%. In the application for adults and adolescents over 14 days in a dose of 5 mg to 20 mg 1 time per day clinically significant drug accumulation is not observed. Simultaneous food intake or grapefruit juice does not affect the distribution of desloratadine at an application rate of 7.5 mg 1 time per day. Desloratadine is not an inhibitor CYP3 A4 and CYP2D6, and is not a substrate or inhibitor of P – glycoprotein. Is extensively metabolized in the liver by hydroxylation to form 3 – OH – desloratadine connected to glucuronide. Only a small part of an oral dose is excreted by the kidneys (
Pregnancy and breast-feeding
Use of the drug in pregnant women is not recommended due to the lack of clinical data on the safety of the drug during pregnancy Erius®.
Desloratadine is excreted into breast milk, so apply Erius® during breastfeeding is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
In children aged 6 to 23 months following side effects were observed, which was slightly higher frequency than with placebo ( “dummy”): diarrhea (3.7% of the cases), fever (2.3%) insomnia (2.3%).
In children aged from 2 to 11 years in the application of the drug Erius® syrup incidence of adverse events was the same as with placebo.
According to the results of clinical trials in children aged 6 to 11 years while taking the drug at the recommended dose (2.5 mg / day) adverse effects have been identified.
Children aged 12 – 17 years on the results of clinical studies the most common side effects – headache (5.9%), which was not the frequency is higher than with placebo (6.9%).
In adults and adolescents (12 years and older) by the results of clinical studies side effects were reported in 3% of patients, compared with the group who used a placebo, it is often observed: fatigue (1.2%), dry mouth spine ( 0.8%), headache (0.6%).
Information about the side effects shown by the results of clinical trials and post-marketing period.
According to the World Health Organization (WHO) side effects are classified according to their frequency of as follows: very often (> 1/10), often (by> 1/100 to
special instructions
Pediatric use.
Efficacy and safety of the drug Erius® syrup in children under 6 months of age has not been established.
Studies of drug efficacy in rhinitis Erius® infectious etiology is not performed.
Effects on ability to drive and use machines.
It should take into account the potential for the development of side effects such as dizziness and somnolence. When the described adverse events should refrain from carrying out these activities.
Storage conditions
At a temperature of not higher than 30 C.
Keep out of the reach of children.
Dosing and Administration
Inside, regardless of mealtime, with a small amount of water.
Children aged 6 to 12 months – 1 mg (2 ml syrup) 1 time per day.
Children aged 1 to 5 years – 1.25 mg (2.5 ml syrup) 1 time per day.
Children aged 6 to 11 years – 2.5 mg (5 ml of syrup) 1 time per day.
Adults and adolescents of 12 years – 5 mg (10 ml of syrup) 1 time per day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist